The 'interferon sensitivity determining region' of hepatitis C virus is a stable sequence element

Journal of Hepatology

Volumn 29, Issue 3, 1998, Pages 352-361

  Rispeter, Kay ^a   Lu, Mengji ^a   Zibert, Andree ^a   Wiese, Manfred ^b   De Oliveira, Jaqueline Mendes ^a,c   Roggendorf, Michael ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b I Klinik für Innere Medizin   (Germany)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Hepatitis C virus (HCV); Interferon sensitivity determining region (ISDR); NS5A protein; RT PCR

Indexed keywords

INTERFERON;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; DRUG RESPONSE; HEPATITIS C; HUMAN; IMMUNOTHERAPY; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0032171325     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80051-2     Document Type: Article

References (46)

1. Cuthbert JA. Hepatits C: progress and problems. Clin Microbiol Rev. 7:1994;505-532.
2. Houghton M. Hepatitis C Viruses. Fields BN, Knipe DM, Howley PM. Fields Virology. 1996;1035-1058 Lippincott-Raven, Philadelphia.
3. Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Semin Liver Dis. 15:1995;64-69.
4. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA. 87:1990;6547-6549.
5. Hoofnagle JH. Therapy of acute and chronic viral hepatitis. Adv Int Med. 39:1994;241-275.
6. Thomas CH, Foster G. Treatment of hepatitis C with interferon: mechanism of action. Nishioka K, Suzuki H, Mishiro S, Oda T. Viral hepatitis and liver disease. 1994;594-600 Springer-Verlag, Berlin, Heidelberg, New York, Tokyo.
7. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol. 21:1994;1-3.
8. Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N, Ikematsu H, et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol. 89:1994;2151-2156.
9. Kohara M, Tanaka T, Tsukiyama KK, Tanaka S, Mizokami M, Lau JY, et al. Hepatitis C virus genotypes 1 and 2 respond to interferon-alpha with different virologic kinetics. J Infect Dis. 172:1995;934-938.
10. Pawlotsky JM, Roudot Thoraval F, Bastie A, Darthuy F, Remire J, et al. Factors affecting treatment responses to interferon-alpha in chronic hepatitis C. J Infect Dis. 174:1996;1-7.
11. Orito E, Mizokami M, Nakano T, Terashima H, Nojiri O, Sakakibara K, et al. Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-alpha therapy in Japanese patients with chronic hepatitis C. J Med Virol. 44:1994;410-414.
12. Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, et al. Comparison of serum hepatitis C virus RNA concentration by branched DNA probe assay with competetive reverse to interferon-alpha therapy in chronic hepatitis C patients. J Med Virol. 48:1996;354-359.
13. Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. (published erratum appears in Lancet 1993 Aug 21; 342(8869): 504) Lancet. 341:1993;1501-1504.
14. Garson JA, Brillanti S, Whitby K, Foli M, Deaville R, Masci C, et al. Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C. J Med Virol. 45:1995;348-353.
15. Le Guen B, Squadrito G, Nalpas B, Berthelot P, Pol S, Brechot C. Hepatitis C virus genome complexity correlates with response to interferon therapy: a study in French patients with chronic hepatitis C. Hepatology. 25:1997;1250-1254.
16. Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, et al. Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. J Hepatol. 26:1997;6-13.
17. Yun ZB, Odeberg J, Lundeberg J, Weiland O, Uhlen M, Sonnerborg A. Restriction of hepatitis C virus heterogeneity during prolonged interferon-alpha therapy in relation to changes in virus load. J Infect Dis. 173:1996;992-996.
18. Gonzalez-Peralta RP, Liu WZ, Davis Gl, Qian KP, Lau JY. Modulation of hepatitis C virus quasispecies heterogeneity by interferon-alpha and ribavirin therapy. J Viral Hepat. 4:1997;99-106.
19. Polyak SJ, Faulkner G, Carithers RLJ, Corey L, Gretch DR. Assessment of hepatitis C virus quasispecies heterogeneity by shift analysis: correlation with response to interferon therapy. J Infect Dis. 175:1997;1101-1107.
20. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the HS5A region. J Clin Invest. 96:1995;224-230.
21. Sakuma I, Enomoto N, Kurosaki M, Marumo F, Sato C. Selection of hepatitis C virus quasispecies during interferon treatment. Arch Virol. 141:1996;1921-1932.
22. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 334:1996;77-81.
23. Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyano Y, et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology. 25:1997;745-749.
24. Khorsi H, Castelain S, Wyseur A, Izopet J, Canva V, Rombout A, et al. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. J Hepatol. 27:1997;72-77.
25. Komatsu H, Fujisawa T, Inui A, Miyagawa Y, Onoue M. Mutations in the nonstructural protein 5A gene and response to interferon therapy in young patients with chronic hepatitis C virus 1b infection. J Med Virol. 53:1997;361-365.
26. Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology. 25:1997;750-753.
27. Zeuzem S, Lee JH, Roth WK. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology. 25:1997;740-744.
28. Kaneko T, Tanji Y, Satoh S, Hijikata M, Asabe S, Kimura K, et al. Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochem Biophys Res Comm. 205:1994;320-326.
29. Tanji Y, Kaneko T, Satoh S, Shimotohno K. Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. J Virol. 69:1995;3980-3986.
30. Gale MJ Jr, Korth MJ, Tang NM, Tan S-L, Hopkins DA, Dever TE, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology. 230:1997;217-227.
31. Meisel H, Reip A, Faltus B, Lu M, Porst H, Weise M, et al. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunolgobulin. Lancet. 345:1995;1209-1211.
32. Wiese M. Die parenteral übertragbaren nonA-nonB-Hepatitiden: Epidemiologie. NonA-nonB-Hepatitis, Virushepatitis C: Forschung und Praxis. 1991;126-157 Gustav Fischer Verlag, Jena.
33. Dittmann S, Roggendorf M, Durkop J, Weise M, Lorbeer B, Deinhardt F. Long-term persistence of hepatitis C virus antibodies in a single source outbreak. J Hepatol. 13:1991;323-327.
34. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
35. Schmid M, Flury R, Buhler H, Havelka J, Grob PJ, Heitz PU. Chronic viral hepatitis B and C: an argument against the conventional classification of chronic hepatitis. Virchows Arch. 425:1994;221-228.
36. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA. 87:1990;9524-9258.
37. Okamoto H, Kojima M, Okada S, Yoshizawa H, Iizuka H, Tanaka T, et al. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology. 190:1992;894-899.
38. Tanaka T, Kato N, Nakagawa M, Ootsuyama Y, Cho MJ, Nakazawa T, et al. Molecular cloning of hepatitis C virus genome from a single Japanese carrier: sequence variation within the same individual and among infected individuals. Virus Res. 23:1992;39-53.
39. Ina Y, Mizokami M, Ohba K, Gojobori T. Reduction of synonymous substitutions in the core protein gene of hepatitis C virus. J Mol Evol. 38:1994;50-56.
40. Cuypers HT, Winkel IN, van der Poel C, Reesink HW, Lelie PN, Houghton M, et al. Analysis of genomic variability of hepatitis C virus. J Hepatol. 13:1991;15-19.
41. Abe K, Inchauspe G, Fujisawa K. Genomic characterization and mutation rate of hepatitis C virus isolated from a patient who contracted hepatitis during an epidemic of non-A, non-B hepatitis in Japan. J Gen Virol. 73:1992;2725-2729.
42. Smith DB, Pathirana S, Davidson F, Lawlor E, Power J, Yap PL, et al. The origin of hepatitis C virus genotypes. J Gen Virol. 78:1997;321-328.
43. Höhne M, Schreier E, Roggendorf M. Sequence variability in the env-coding region of hepatitis C virus isolated from patients infected during a single source outbreak. Arch Virol. 137:1994;25-34.
44. Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci USA. 89:1992;3468-3472.
45. van Doorn LJ, Capriles I, Maertens G, DeLeys R, Murray K, Kos T, et al. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune response. J Virol. 69:1995;773-778.
46. Zibert A, Schreier E, Roggendorf M. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology. 208:1995;653-661.